Amgen Inc

Drug Manufacturers-General

Prices are adjusted according to historical splits.

Amgen Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$122.13 billion
Book Value:
Revenue TTM:
$26.32 billion
Operating Margin TTM:
Gross Profit TTM:
$19.92 billion
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Amgen Inc had its IPO on 1983-06-17 under the ticker symbol AMGN.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. Amgen Inc has a staff strength of 25,200 employees.

Stock update

Shares of Amgen Inc opened at $233.57 at the start of the last trading session i.e. 2023-03-19.

The stocks traded within a range of $228.52 - $233.81, and closed at $229.79.

This is a -2.04% slip from the previous day's closing price.

A total volume of 7,817,000 shares were traded at the close of the day’s session.

In the last one week, shares of Amgen Inc have increased by +1.77%.

Amgen Inc's Key Ratios

Amgen Inc has a market cap of $122.13 billion, indicating a price to book ratio of 39.6029 and a price to sales ratio of 5.4945.

In the last 12-months Amgen Inc’s revenue was $26.32 billion with a gross profit of $19.92 billion and an EBITDA of $13.49 billion. The EBITDA ratio measures Amgen Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Amgen Inc’s operating margin was 38.25% while its return on assets stood at 9.97% with a return of equity of 126.47%.

In Q4, Amgen Inc’s quarterly earnings growth was a negative -10.9% while revenue growth was a negative 0.1%.

Amgen Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $12.1 per share while it has a forward price to earnings multiple of 14.9477 and a PEG multiple of 1.5503. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Amgen Inc’s profitability.

Amgen Inc stock is trading at a EV to sales ratio of 6.5285 and a EV to EBITDA ratio of 13.848. Its price to sales ratio in the trailing 12-months stood at 5.4945.

Amgen Inc stock pays annual dividends of $7.76 per share, indicating a yield of 3.73% and a payout ratio of 44.94%.

Balance sheet and cash flow metrics

Total Assets
$65.12 billion
Total Liabilities
$15.69 billion
Operating Cash Flow
Capital Expenditure
$340 million
Dividend Payout Ratio

Amgen Inc ended 2023 with $65.12 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $65.12 billion while shareholder equity stood at $3.66 billion.

Amgen Inc ended 2023 with $0 in deferred long-term liabilities, $15.69 billion in other current liabilities, 32514000000.00 in common stock, $-18048000000.00 in retained earnings and $15.53 billion in goodwill. Its cash balance stood at $7.63 billion and cash and short-term investments were $9.31 billion. The company’s total short-term debt was $1,591,000,000 while long-term debt stood at $37.35 billion.

Amgen Inc’s total current assets stands at $22.19 billion while long-term investments were $0 and short-term investments were $1.68 billion. Its net receivables were $5.56 billion compared to accounts payable of $1.57 billion and inventory worth $4.93 billion.

In 2023, Amgen Inc's operating cash flow was $-3473000000.00 while its capital expenditure stood at $340 million.

Comparatively, Amgen Inc paid $0.45 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Amgen Inc stock is currently trading at $229.79 per share. It touched a 52-week high of $292.065 and a 52-week low of $292.065. Analysts tracking the stock have a 12-month average target price of $258.76.

Its 50-day moving average was $245.29 and 200-day moving average was $248.26 The short ratio stood at 2.81 indicating a short percent outstanding of 0%.

Around 20.9% of the company’s stock are held by insiders while 7993.9% are held by institutions.

Frequently Asked Questions About Amgen Inc

The stock symbol (also called stock or share ticker) of Amgen Inc is AMGN

The IPO of Amgen Inc took place on 1983-06-17

Similar Industry Stocks (Drug Manufacturers-General)

Last Price
Gifa Inc (GIFX)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price


Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.


One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799